|
|
Logo
Logo Logo

Category Archives: "News"

  1. Home
  2. INforMS
  3. Page 44
Oct 06, 2015
Opexa announces granting of new t-cell patents covering tcelna
INforMS
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized [...]
Elizabeth Porco
Read More
...18
0
Oct 05, 2015
Genzyme introduces “vs.MS”, a global initiative
INforMS, MS Community, Partners
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed [...]
Elizabeth Porco
Read More
...17
0
Sep 27, 2015
Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study
INforMS, Partners
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large [...]
Elizabeth Porco
Read More
...16
0
Sep 25, 2015
Bayer receives FDA approval for BETACONNECT
INforMS, Partners
Intended for U.S. Media Only Whippany, N.J., September 25, 2015 – Bayer HealthCare announced today that the U.S. Food and Drug [...]
Elizabeth Porco
Read More
...17
0
Aug 21, 2015
Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis
INforMS, Partners
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications Novartis [...]
Elizabeth Porco
Read More
...16
0
Aug 09, 2015
EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
INforMS, Partners
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Elizabeth Porco
Read More
...15
0
Aug 03, 2015
Pfizer & Synthon enter Into U.S. commercialization agreement for treatment of multiple sclerosis
INforMS
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today [...]
Elizabeth Porco
Read More
...15
0
Jul 28, 2015
FDA: Gadolinium-based MRI contrast agents pose possible brain risk
INforMS
A statement from our CMSC leadership: While the implications for MS patient care may need to be re-evaluated and changed in the future [...]
Elizabeth Porco
Read More
...16
0
Jul 10, 2015
Multiple Sclerosis Coalition applauds passage of 21st Century Cures Act
MS Community, Partners
Multiple Sclerosis Coalition Applauds Passage of 21st Century Cures Act Inclusion of data-gathering provision is vital to future MS [...]
Elizabeth Porco
Read More
...16
0
Jun 29, 2015
Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
INforMS, Partners
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Elizabeth Porco
Read More
...17
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last